Stealth BioTherapeutics Corp (NASDAQ:MITO) Expected to Post Earnings of -$0.03 Per Share
Wall Street analysts predict that Stealth BioTherapeutics Corp (NASDAQ:MITO) will post earnings per share of ($0.03) for the current quarter, Zacks reports. Zero analysts have provided estimates for Stealth BioTherapeutics’ earnings. Stealth BioTherapeutics reported earnings per share of ($0.04) during the same quarter last year, which suggests a positive year-over-year growth rate of 25%. The firm is expected to report its next earnings report on Wednesday, August 12th.
According to Zacks, analysts expect that Stealth BioTherapeutics will report full year earnings of ($0.11) per share for the current fiscal year, with EPS estimates ranging from ($0.13) to ($0.08). For the next financial year, analysts forecast that the business will report earnings of ($0.07) per share, with EPS estimates ranging from ($0.09) to ($0.06). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that follow Stealth BioTherapeutics.
Stealth BioTherapeutics (NASDAQ:MITO) last posted its earnings results on Wednesday, April 1st. The company reported $0.12 EPS for the quarter, beating the consensus estimate of ($0.04) by $0.16. The business had revenue of $21.09 million during the quarter.
Shares of MITO stock traded down $0.05 during mid-day trading on Tuesday, hitting $1.85. 84,600 shares of the stock were exchanged, compared to its average volume of 397,083. The stock’s fifty day simple moving average is $2.01 and its two-hundred day simple moving average is $2.65. The stock has a market capitalization of $65.51 million, a price-to-earnings ratio of -1.04 and a beta of 2.79. Stealth BioTherapeutics has a 12-month low of $0.90 and a 12-month high of $14.41.
An institutional investor recently bought a new position in Stealth BioTherapeutics stock. Prosight Management LP acquired a new stake in Stealth BioTherapeutics Corp (NASDAQ:MITO) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 336,167 shares of the company’s stock, valued at approximately $417,000. Prosight Management LP owned 0.96% of Stealth BioTherapeutics as of its most recent SEC filing. 2.18% of the stock is currently owned by institutional investors and hedge funds.
Stealth BioTherapeutics Company Profile
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases.
See Also: Dead Cat Bounce
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Stealth BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stealth BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.